Outlook Therapeutics Special Meeting on July 16 to Vote on Warrant Issuance, Share Increase, and Reverse Split

Outlook Therapeutics, Inc. has filed a definitive proxy statement (DEF 14A) for a Special Meeting of Stockholders scheduled for July 16, 2026. The meeting will address four key proposals: approval of the potential issuance of shares underlying various warrants issued in connection with a registered direct offering and private placement, an increase in the total number of authorized shares of common stock from 260 million to 600 million, and approval of a reverse stock split. The Board of Directors recommends a vote 'For' all proposals.